TERM ID="NYU_TERM_1" STRING="ALT" FREQUENCY=1 START=817 END=820 LEMMA="ALT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="CHB" FREQUENCY=1 START=229 END=232 LEMMA="CHRONIC HEPATITIS B" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_3" STRING="Clinical Excellence" FREQUENCY=1 START=338 END=357 LEMMA="CLINICAL EXCELLENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="DNA suppression" FREQUENCY=1 START=774 END=789 LEMMA="DNA SUPPRESSION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_5" STRING="Entecavir" FREQUENCY=2 START=0 END=9 LEMMA="ENTECAVIR" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_6" STRING="Entecavir" FREQUENCY=2 START=1816 END=1825 LEMMA="ENTECAVIR" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_7" STRING="HBV" FREQUENCY=1 START=769 END=772 LEMMA="HEPATITIS B VIRUS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_8" STRING="HBeAg" FREQUENCY=1 START=946 END=951 LEMMA="HEPATITIS B E ANTIGEN" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_9" STRING="HBeAg-negative hepatitis B" FREQUENCY=1 START=3348 END=3374 LEMMA="HBEAG-NEGATIVE HEPATITIS B" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_10" STRING="HBeAg-negative model" FREQUENCY=1 START=2933 END=2953 LEMMA="HBEAG-NEGATIVE MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="HBeAg-negative patients" FREQUENCY=3 START=1412 END=1435 LEMMA="HBEAG-NEGATIVE PATIENT" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_12" STRING="HBeAg-negative patients" FREQUENCY=3 START=1859 END=1882 LEMMA="HBEAG-NEGATIVE PATIENT" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_13" STRING="HBeAg-negative patients" FREQUENCY=3 START=2773 END=2796 LEMMA="HBEAG-NEGATIVE PATIENT" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_14" STRING="HBeAg-positive" FREQUENCY=1 START=1386 END=1400 LEMMA="HBEAG-POSITIVE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_15" STRING="HBeAg-positive lamivudine-refractory patients" FREQUENCY=1 START=2063 END=2108 LEMMA="HBEAG-POSITIVE LAMIVUDINE-REFRACTORY PATIENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_16" STRING="HBeAg-positive patients" FREQUENCY=2 START=1573 END=1596 LEMMA="HBEAG-POSITIVE PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_17" STRING="HBeAg-positive patients" FREQUENCY=2 START=2842 END=2865 LEMMA="HBEAG-POSITIVE PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_18" STRING="ICER" FREQUENCY=2 START=1650 END=1654 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_19" STRING="ICER" FREQUENCY=2 START=2462 END=2466 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_20" STRING="ICERs" FREQUENCY=1 START=2302 END=2307 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIOS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_21" STRING="MTC" FREQUENCY=1 START=1115 END=1118 LEMMA="MIXED TREATMENT COMPARISON" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_22" STRING="Markov state transition models" FREQUENCY=1 START=1347 END=1377 LEMMA="MARKOV STATE TRANSITION MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_23" STRING="QALY" FREQUENCY=4 START=1796 END=1800 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_24" STRING="QALY" FREQUENCY=4 START=2041 END=2045 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_25" STRING="QALY" FREQUENCY=4 START=2351 END=2355 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_26" STRING="QALY" FREQUENCY=4 START=2511 END=2515 LEMMA="QUALITY ADJUSTED LIFE YEAR" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_27" STRING="RCTs" FREQUENCY=1 START=494 END=498 LEMMA="RANDOMISED CONTROLLED TRIALS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_28" STRING="STA" FREQUENCY=1 START=409 END=412 LEMMA="SINGLE TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_29" STRING="STA states" FREQUENCY=1 START=3235 END=3245 LEMMA="STA STATE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_30" STRING="achieving hepatitis B e antigen" FREQUENCY=1 START=913 END=944 LEMMA="ACHIEVING HEPATITIS B E ANTIGEN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="achieving hepatitis B virus" FREQUENCY=1 START=740 END=767 LEMMA="ACHIEVING HEPATITIS B VIRUS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_32" STRING="alanine aminotransferase" FREQUENCY=1 START=791 END=815 LEMMA="ALANINE AMINOTRANSFERASE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_33" STRING="antiviral treatment" FREQUENCY=1 START=3383 END=3402 LEMMA="ANTIVIRAL TREATMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_34" STRING="base-case" FREQUENCY=1 START=1601 END=1610 LEMMA="BASE-CASE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_35" STRING="base-case ICERs" FREQUENCY=1 START=1887 END=1902 LEMMA="BASE-CASE ICER" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="base-case incremental cost-effectiveness ratios" FREQUENCY=1 START=1601 END=1648 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO BASE-CASE" LEMMA_FREQUENCY=1 HEAD_TERM="incremental cost-effectiveness ratios" HEAD_LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO"
TERM ID="NYU_TERM_37" STRING="chronic HBeAg-positive" FREQUENCY=1 START=3322 END=3344 LEMMA="CHRONIC HBEAG-POSITIVE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_38" STRING="chronic hepatitis B" FREQUENCY=2 START=208 END=227 LEMMA="CHRONIC HEPATITIS B" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_39" STRING="chronic hepatitis B" FREQUENCY=2 START=208 END=227 LEMMA="CHRONIC HEPATITIS B" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_40" STRING="chronic hepatitis B infection" FREQUENCY=1 START=31 END=60 LEMMA="CHRONIC HEPATITIS B INFECTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_41" STRING="comparator drugs" FREQUENCY=1 START=1156 END=1172 LEMMA="COMPARATOR DRUG" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_42" STRING="comparing entecavir" FREQUENCY=1 START=587 END=606 LEMMA="COMPARING ENTECAVIR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_43" STRING="controlled trials" FREQUENCY=1 START=475 END=492 LEMMA="CONTROLLED TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_44" STRING="cost-effectiveness" FREQUENCY=1 START=155 END=173 LEMMA="COST-EFFECTIVENESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_45" STRING="cost-effectiveness of entecavir" FREQUENCY=1 START=155 END=186 LEMMA="ENTECAVIR COST-EFFECTIVENESS" LEMMA_FREQUENCY=1 HEAD_TERM="cost-effectiveness" HEAD_LEMMA="COST-EFFECTIVENESS"
TERM ID="NYU_TERM_46" STRING="deterministic sensitivity analysis" FREQUENCY=1 START=2170 END=2204 LEMMA="DETERMINISTIC SENSITIVITY ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_47" STRING="dominated adefovir" FREQUENCY=1 START=2119 END=2137 LEMMA="DOMINATED ADEFOVIR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_48" STRING="economic evaluation" FREQUENCY=1 START=1294 END=1313 LEMMA="ECONOMIC EVALUATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_49" STRING="entecavir" FREQUENCY=4 START=177 END=186 LEMMA="ENTECAVIR" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_50" STRING="entecavir" FREQUENCY=4 START=2471 END=2480 LEMMA="ENTECAVIR" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_51" STRING="entecavir" FREQUENCY=4 START=3058 END=3067 LEMMA="ENTECAVIR" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_52" STRING="entecavir" FREQUENCY=4 START=3251 END=3260 LEMMA="ENTECAVIR" LEMMA_FREQUENCY=6
TERM ID="NYU_TERM_53" STRING="evidence review group" FREQUENCY=1 START=98 END=119 LEMMA="EVIDENCE REVIEW GROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_54" STRING="hepatitis B e antigen" FREQUENCY=1 START=923 END=944 LEMMA="HEPATITIS B E ANTIGEN" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_55" STRING="hepatitis B virus" FREQUENCY=1 START=750 END=767 LEMMA="HEPATITIS B VIRUS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_56" STRING="histological improvement" FREQUENCY=1 START=840 END=864 LEMMA="HISTOLOGICAL IMPROVEMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_57" STRING="incremental cost-effectiveness ratios" FREQUENCY=2 START=1611 END=1648 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_58" STRING="incremental cost-effectiveness ratios" FREQUENCY=2 START=1611 END=1648 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_59" STRING="interferon alpha-2a" FREQUENCY=2 START=1953 END=1972 LEMMA="INTERFERON ALPHA-2A" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_60" STRING="interferon alpha-2a" FREQUENCY=2 START=2573 END=2592 LEMMA="INTERFERON ALPHA-2A" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_61" STRING="key input parameters" FREQUENCY=1 START=2212 END=2232 LEMMA="KEY INPUT PARAMETER" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_62" STRING="lamivudine" FREQUENCY=5 START=612 END=622 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_63" STRING="lamivudine" FREQUENCY=5 START=1684 END=1694 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_64" STRING="lamivudine" FREQUENCY=5 START=1931 END=1941 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_65" STRING="lamivudine" FREQUENCY=5 START=2261 END=2271 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_66" STRING="lamivudine" FREQUENCY=5 START=2551 END=2561 LEMMA="LAMIVUDINE" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_67" STRING="life-year" FREQUENCY=1 START=1785 END=1794 LEMMA="LIFE-YEAR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_68" STRING="lifetime treatment" FREQUENCY=1 START=3017 END=3035 LEMMA="LIFETIME TREATMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_69" STRING="lifetime treatment scenario" FREQUENCY=1 START=2741 END=2768 LEMMA="LIFETIME TREATMENT SCENARIO" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_70" STRING="lifetime treatment scenario for HBeAg-negative patients" FREQUENCY=1 START=2741 END=2796 LEMMA="HBEAG-NEGATIVE PATIENT LIFETIME TREATMENT SCENARIO" LEMMA_FREQUENCY=1 HEAD_TERM="lifetime treatment scenario" HEAD_LEMMA="LIFETIME TREATMENT SCENARIO"
TERM ID="NYU_TERM_71" STRING="manufacturer" FREQUENCY=4 START=270 END=283 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_72" STRING="manufacturer" FREQUENCY=4 START=1071 END=1084 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_73" STRING="manufacturer" FREQUENCY=4 START=1318 END=1330 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_74" STRING="manufacturer" FREQUENCY=4 START=2725 END=2738 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_75" STRING="methodological quality" FREQUENCY=1 START=509 END=531 LEMMA="METHODOLOGICAL QUALITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_76" STRING="mixed treatment comparison" FREQUENCY=1 START=1087 END=1113 LEMMA="MIXED TREATMENT COMPARISON" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_77" STRING="normalisation" FREQUENCY=1 START=822 END=835 LEMMA="NORMALISATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_78" STRING="nucleoside-naive HBeAg-negative patients" FREQUENCY=1 START=2626 END=2666 LEMMA="NUCLEOSIDE-NAIVE HBEAG-NEGATIVE PATIENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_79" STRING="nucleoside-naive HBeAg-positive patients" FREQUENCY=1 START=2398 END=2438 LEMMA="NUCLEOSIDE-NAIVE HBEAG-POSITIVE PATIENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_80" STRING="nucleoside-naive patients" FREQUENCY=2 START=1176 END=1201 LEMMA="NUCLEOSIDE-NAIVE PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_81" STRING="nucleoside-naive patients" FREQUENCY=2 START=2275 END=2300 LEMMA="NUCLEOSIDE-NAIVE PATIENT" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_82" STRING="one-way" FREQUENCY=1 START=2162 END=2169 LEMMA="ONE-WAY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_83" STRING="one-way deterministic sensitivity analysis" FREQUENCY=1 START=2162 END=2204 LEMMA="DETERMINISTIC SENSITIVITY ANALYSIS ONE-WAY" LEMMA_FREQUENCY=1 HEAD_TERM="deterministic sensitivity analysis" HEAD_LEMMA="DETERMINISTIC SENSITIVITY ANALYSIS"
TERM ID="NYU_TERM_84" STRING="pegylated interferon alpha-2a" FREQUENCY=1 START=1699 END=1728 LEMMA="PEGYLATED INTERFERON ALPHA-2A" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_85" STRING="probabilistic sensitivity analysis" FREQUENCY=1 START=2360 END=2394 LEMMA="PROBABILISTIC SENSITIVITY ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_86" STRING="probability" FREQUENCY=1 START=2443 END=2454 LEMMA="PROBABILITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_87" STRING="probability of the ICER" FREQUENCY=1 START=2443 END=2466 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO PROBABILITY" LEMMA_FREQUENCY=1 HEAD_TERM="probability" HEAD_LEMMA="PROBABILITY"
TERM ID="NYU_TERM_88" STRING="probability of the ICER for entecavir" FREQUENCY=1 START=2443 END=2480 LEMMA="ENTECAVIR INCREMENTAL COST EFFECTIVENESS RATIO PROBABILITY" LEMMA_FREQUENCY=1 HEAD_TERM="probability of the ICER" HEAD_LEMMA="INCREMENTAL COST EFFECTIVENESS RATIO PROBABILITY"
TERM ID="NYU_TERM_89" STRING="quality-adjusted life-year" FREQUENCY=1 START=1768 END=1794 LEMMA="QUALITY-ADJUSTED LIFE-YEAR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_90" STRING="randomised controlled trials" FREQUENCY=1 START=464 END=492 LEMMA="RANDOMISED CONTROLLED TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_91" STRING="seroconversion" FREQUENCY=1 START=953 END=967 LEMMA="SEROCONVERSION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_92" STRING="single technology appraisal" FREQUENCY=1 START=380 END=407 LEMMA="SINGLE TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_93" STRING="structural assumptions" FREQUENCY=1 START=1546 END=1568 LEMMA="STRUCTURAL ASSUMPTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_94" STRING="subject" FREQUENCY=1 START=1486 END=1493 LEMMA="SUBJECT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_95" STRING="technology appraisal" FREQUENCY=1 START=387 END=407 LEMMA="TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_96" STRING="telbivudine" FREQUENCY=2 START=1843 END=1854 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_97" STRING="telbivudine" FREQUENCY=2 START=1977 END=1988 LEMMA="TELBIVUDINE" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_98" STRING="treatment comparison" FREQUENCY=1 START=1093 END=1113 LEMMA="TREATMENT COMPARISON" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_99" STRING="treatment entecavir" FREQUENCY=1 START=640 END=659 LEMMA="TREATMENT ENTECAVIR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_100" STRING="treatment scenario" FREQUENCY=1 START=2819 END=2837 LEMMA="TREATMENT SCENARIO" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_101" STRING="treatment scenario for HBeAg-positive patients" FREQUENCY=1 START=2819 END=2865 LEMMA="HBEAG-POSITIVE PATIENT TREATMENT SCENARIO" LEMMA_FREQUENCY=1 HEAD_TERM="treatment scenario" HEAD_LEMMA="TREATMENT SCENARIO"
